今年10月10日是第34个世界精神卫生日。当日，"人人享有心理健康服务"大型义诊活动在西安启 动。 活动现场设置12个主题专区，精准匹配不同群体需求。儿童青少年专区结合案例化解厌学、考前焦 虑，孕产妇专区提供孕期情绪管理方案并发放专属手册，老年人专区围绕痴呆预防、空巢心理关怀展开 服务。活动当日累计服务5500余名市民，解答政策与资源咨询5500余条，发放宣传品3180份。 活动通过"三级义诊、双线传播、多元互动"的体系化服务模式，将专业心理服务下沉基层。陕西省 精神卫生中心·西安市精神卫生中心专家与"12356"心理服务热线团队提供精神科诊疗、危机干预等服 务；西安市10余个区县及开发区精防机构、综合医院精神科组建专项队伍，针对区域高发心理问题开展 靶向答疑，打通服务"区域壁垒"；17个社区卫生服务中心聚焦基础健康评估与知识普及，让老年人、孕 产妇、儿童青少年等重点人群在"家门口"享受服务。 西安市卫生健康委相关负责人表示，将进一步强化"市—区—社区"三级服务网络联动，推动心理健 康服务与公共卫生体系、社区治理体系深度融合，常态化开展便民宣传与义诊服务。 （记者：张家 祯） 本次活动由西安市卫生健康委员会牵 ...

Core Insights - Optavise has announced a strategic partnership with Rula to enhance access to mental health services for employees and their families [1][3] - The partnership allows Optavise Clear clients to utilize Rula's network of over 21,000 licensed behavioral health professionals at no additional cost [2][4] Company Overview - Optavise specializes in personalized employee benefits solutions, aiming to help employers and employees optimize their benefits and make informed health and financial decisions [5] - Rula is a behavioral healthcare provider group focused on making high-quality mental healthcare accessible, with a network covering over 170 million people [4][6] Partnership Benefits - The collaboration aims to simplify the wellness experience for employees by providing a streamlined connection to trusted care [3] - Key features of Rula's services include rapid appointment availability, a guided scheduling experience, and rigorous clinical quality standards [7]

Central, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Central, HK September 29, 2025 - - Maple Tree Counselling, a boutique counselling and therapy practice in Central, Hong Kong, has announced the addition of two certified therapists to its growing team. Julia Laubscher and Varuna Vaswani bring specialized expertise in trauma-informed care and couples counselling, expanding the practice's capacity to serve the city's diverse, multicultural community. For more information, visit: https://www.mapletreecounselling.com ...

[موسيقى] السلام عليكم في ليله سبت هادئه من عام 2020 الساعه بعد منتصف الليل جاني اتصال في البدايه جهلت الاتصال ش السبب اللي خليني ارد على اتصال بعد الساعه حده بعدها بدقائق رن جوالي مره ثانيه وجهت الاتصال بعدها بدقائق رنج للمره الثالثه هالمره قررت ارد على اتصال وما كنت اعرف ان هذا الاتصال راح يغير مسار حياتي بعدها تماما الو هلا ابراهيم ابراهيم هو مدير العمليات في لبيه واللي ما يعرف لبيه لبيه هي منصه لتقديم خدمات الارشاد والجلسات النفسيه هلا ابراهيم اهلين هلا مازن مازن عندنا حاله طارئه فيه عميله اخذت جلسه قبل ...

Core Insights - Trinity Capital Inc. has committed $26 million in growth capital to Unmind, a workplace mental health platform that integrates AI to provide comprehensive mental health care solutions [1][4]. - Unmind's platform combines human expertise, digital innovation, and proven science to offer a range of services including proactive AI guidance, therapy, coaching, crisis care, and wellbeing tracking [2][6]. - The funding will enable Unmind to scale operations, enhance its AI agent "Nova," attract talent, and invest in further innovation, bringing Unmind's total capital raised to over $100 million since its inception [4][5]. Company Overview - Trinity Capital Inc. is an alternative asset manager focused on delivering consistent returns through private credit markets, having deployed over $4.7 billion across more than 420 investments since 2008 [5]. - Unmind supports nearly 3 million employees globally, including major brands like Uber, Disney, and Major League Baseball, emphasizing the importance of mental health in the workplace [3][6].

Core Viewpoint - BrainsWay is strategically investing in minority positions in leading U.S. mental health providers to enhance awareness and access to innovative mental health treatments, particularly Deep TMS Therapy [1][2]. Investment Details - BrainsWay has entered into a strategic equity financing agreement with Axis Management Company, Inc., committing an initial investment of $2.3 million, with a potential additional $1 million based on milestones [1]. - The investment will be in the form of a preferred, annually compounding security, and includes a redemption mechanism for the shares [1]. Strategic Goals - The investment in Axis is part of BrainsWay's broader initiative to accelerate access to innovative mental health treatments while maintaining a focus on advancing scientific and technological capabilities [2]. - The company aims to provide capital injections into high-performing healthcare providers, enabling them to invest in growth and expand their services [2]. Axis Management Company Overview - Axis Integrated Mental Health is a management services organization that operates several mental health clinics in Colorado, focusing on delivering comprehensive and integrative care [4]. - The organization combines modern psychiatry and psychotherapy with advanced treatments, including Deep TMS and Spravato, to provide a holistic therapeutic approach [4]. BrainsWay Overview - BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, particularly known for its proprietary Deep TMS technology [3]. - The company has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and is committed to increasing global awareness and access to Deep TMS [3].

Financial Data and Key Metrics Changes - Revenue grew 11% year over year to $345 million, driven by better-than-expected clinician productivity and total revenue per visit [13] - Adjusted EBITDA increased 19% year over year to $34 million, with adjusted EBITDA margin at 9.8% [15] - Free cash flow reached $57 million, the highest in the company's history, with a solid cash position of $189 million [16] Business Line Data and Key Metrics Changes - The clinician base increased by 173 clinicians this quarter, totaling 7,780 clinicians, an 11% year-over-year increase [14] - Visit volumes rose 12% year over year to 2.2 million, primarily driven by clinician growth [13] Market Data and Key Metrics Changes - The company expects to achieve mid-teens revenue growth in 2026, supported by increasing demand for mental health services [12] - The company anticipates a low to mid single-digit rate improvement and continued organic growth of the clinician base [12] Company Strategy and Development Direction - The company is focused on expanding access to high-quality and affordable mental healthcare, leveraging both in-person and virtual care [6] - Investments in technology, including AI and digital solutions, are aimed at improving operational efficiency and clinician satisfaction [10][11] - The company is exploring M&A opportunities for geographic expansion, particularly in new markets [76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic healthcare environment and achieving double-digit margins for the full year [6][18] - The company is optimistic about the future, expecting to benefit from industry tailwinds and increasing demand for mental health services [20] Other Important Information - The company has implemented a patient engagement platform to improve acquisition and retention [8] - A new Chief Technology Officer has been appointed to lead digital transformation initiatives [11] Q&A Session Summary Question: Confidence level for Q4 ramp and productivity improvements - Management expressed strong confidence in revenue growth for the second half of the year, expecting approximately $60 million of revenue growth driven by visit volume and rate increases [26] Question: Clinician adds and retention dynamics - Management noted stable retention and strong recruiting, validating the company's value proposition in a competitive environment [30] Question: Updates on managed care contracting and cash pay shift - Management highlighted a trend of patients shifting from cash pay to insurance, which is expected to benefit the company [34] Question: Sustainability of volume growth and productivity initiatives - Management detailed that productivity initiatives are expected to contribute significantly to volume growth, with a focus on filling clinician schedules [41] Question: Free cash flow outlook - Management indicated that while Q3 cash flow may decrease due to various factors, the overall trajectory for free cash flow remains positive [48] Question: Impact of AI tools and EHR initiative - Management stated that AI tools are being implemented to improve efficiency and clinician experience, with ongoing evaluation of EHR solutions [98]

Financial Performance - Q2 2025 revenue reached $345.3 million, an 11% year-over-year increase[9] - Q2 2025 Center Margin was $108.4 million, representing 31.4% of revenue[9] - Q2 2025 Adjusted EBITDA was $34.0 million, or 9.8% of revenue[9] - The company ended Q2 2025 with a cash position of $188.9 million[9] - Full year 2025 revenue guidance is reaffirmed at $1.40 billion - $1.44 billion[19] - Full year 2025 Adjusted EBITDA guidance is raised to $140 million - $150 million[19] Operational Metrics - Total clinicians reached 7,708, an 11% year-over-year growth, with 173 net clinician additions in Q2[9, 8] - Q2 2025 visit volumes increased by 12% year-over-year to 2.2 million[9] - The company operates over 550 centers in 33 states[8] Balance Sheet and Capital Allocation - Cash and cash equivalents totaled $189 million[17] - Net long-term debt is $273 million[17]

Financial Data and Key Metrics Changes - Total revenue for the second quarter was $38.1 million, an 18% year-over-year increase on an adjusted pro forma basis [7][25] - Revenue from the NeuroStar business was $15.1 million, with U.S. treatment session revenue increasing by 13% on a pro forma basis [7][27] - Gross margin decreased to 46.6% compared to 74% in the prior year quarter, primarily due to the inclusion of Green Brook's lower-margin clinic business [28] - Net loss for the quarter was $9.8 million, or $0.15 per share, compared to a net loss of $9.8 million, or $0.33 per share, in the prior year quarter [29] Business Line Data and Key Metrics Changes - NeuroStar system revenue was $3.5 million with 41 systems shipped, demonstrating a strong average selling price [27] - U.S. clinic revenue reached $23 million, marking the strongest quarterly performance for Green Brook [28] - The Better Me Provider (BMP) program has 395 active sites, treating three times more patients per site compared to non-BMP practices [13][14] Market Data and Key Metrics Changes - The company has seen a 25% growth in adolescent new patient starts in 2025 compared to 2024, driven by increased insurance coverage [20] - The publication of clinical data in a reputable journal highlighted the effectiveness of the NeuroStar TMS system in adolescents, with nearly 70% experiencing clinically meaningful improvement [21] Company Strategy and Development Direction - The company is focusing on three strategic priorities: executing the Green Brook growth strategy, scaling the BMP program, and improving operational efficiencies [8][9] - The Green Brook growth strategy has exceeded expectations, with improved patient conversion rates through enhanced patient connection capabilities [10] - The company is taking a thoughtful approach to expanding the buy and bill model for SPRAVATO, focusing on opportunities that deliver good margins [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity by the end of 2025, supported by operational improvements and strategic initiatives [35] - The integration of Neuronetics and Green Brook is creating significant value, positioning the company for sustainable growth and profitability [36] Other Important Information - Cash used in operations for the second quarter was $3.5 million, better than the previously guided target of under $5 million [31] - The company has received additional funding under its existing debt agreement, enhancing financial flexibility [30] Q&A Session Summary Question: Dynamics of traditional NeuroStar business vs. Green Brook - Management indicated that the shift in strategy towards provider connections is expected to improve conversion rates over time, despite a slower growth in traditional NeuroStar business [40][42] Question: Impact of marketing strategy on long-term spending - The new strategy is anticipated to make marketing dollars more efficient, potentially lowering overall marketing spend while still requiring some investment in educational efforts [43][44] Question: Resubmitted claims and reimbursement timing - Management is focused on improving revenue cycle management and expects to see a tailwind from catching up on aged claims while enhancing the efficiency of new claims [46][48] Question: Clinical sales per site and long-term expectations - Management did not provide a specific target for clinical sales per site but indicated that revenue trends and site performance would continue to improve [53][55] Question: Marketing strategy for adolescent patients - The company is targeting providers who care for adolescent patients through the Provider Connection program, which has shown positive results in driving awareness and adoption [59]

Company Overview - Neuronetics and Greenbrook have combined to leverage scale and capabilities for mental health treatment[17] - The combined company has treated 221,376 unique patients[18] and administered 7,912,427 treatments[19] - The company reported $129 million in annual revenue for 2024 (pro forma adjusted)[19] Market and Opportunity - The total available market is 293 million U S adults and adolescents suffering from depression, depression with anxiety, and OCD[33,34] - Approximately 8 million patients are poorly served by antidepressant medication[34] - Better Me Program (BMP) clinics treat 33 times more patients than non-BMP clinics[57,58] Financial Performance and Guidance - Q2 2025 revenue was $381 million, a 132% increase from Q2 2024[90] - The company projects revenue between $149 million and $155 million for FY 2025, representing a 15% to 19% pro forma year-over-year growth[85] - The company anticipates achieving positive cash flow from operations in Q4 2025[85]